News

Drug Discovered in Canada Now Approved in Canada

Great news to all our TPN patients. REVESTIVE is now available in Canada through the exceptional Access Program (EAP).

The novel drug shows breakthrough results in treating the rare but debilitating condition known as Short Bowel Syndrome (SBS).

It is there first long-term treatment advance for this condition in nearly 40 years. It promotes repair and normal growth of the intestine and increases the absorption of nutrients in patients with this condition.

It’s exciting to know REVESTIVE has significant impact on the quality of TPN patients’ lives.

Concord Specialty Pharmacy is full ready to coordinate with TPN patients and their healthcare teams to initiate REVESTIVE therapy when necessary.